Market Research Report
Competitor Analysis: Bispecific Antibodies for Immuno-Oncology & Other Diseases
|Published by||La Merie Publishing||Product code||890224|
|Published||Content info||125 Pages
Delivery time: 1-2 business days
|Competitor Analysis: Bispecific Antibodies for Immuno-Oncology & Other Diseases|
|Published: June 30, 2019||Content info: 125 Pages||
This Competitive Intelligence report about Bispecific Antibodies for Immuno-Oncology & Other Diseases evaluates the landscape of investigational bispecific therapeutic antibodies for treatment of cancer, inflammatory & autoimmune diseaseas as well as cardiometabolic, infectious, neurologic and ophthalmic diseases as of June 2019.
At present, only two bispecific therapeutic monoclonal antibodies are on the market, one for leukemia and one for hemophilia. La Merie Publishing conducted a search for bispecific monoclonal antibodies (and some multimeric proteins) in R&D. The search identified 271 unique bispecific antibody-based constructs in active R&D (excluding discontinued developments of bispecifics). Of the 110 clinical stage bispecific antibodies, 50% are used for redirection of T-cells to a tumor target. More than 85% of the clinical stage bispecific molecules are in development for treatment of cancer. The combination of immune checkpoint inhibitor and/or activator targets is a strongly emerging use of the bispecific antibody technology. The traditonal application of bispecifics for targeting two tumor-associated antigens (or epitopes) and/or growth factors is a field with strong clinical activities, but the non-clinical pipeline is relatively empty compared with immuno-oncology bispecifics (11 vs 48 projects).
The report highlights the use of bispecific antibody technology for generation of
The report includes a compilation of currently active projects in research and development of bispecific therapeutic antibodies in cancer and non-cancer indications. Competitor projects are listed in a tabular format providing information on:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies. The information is provided in a tabular format and fully referenced.